View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
In association with Cytiva for Cell & Gene Therapy coverage
  1. News
January 7, 2022

FDA grants IND clearance for REGENXBIO’s gene therapy trial for Duchenne

Set to commence in the first half of this year, the trial will initially have sites in the US.

The US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of REGENXBIO to initiate a first-in-human clinical trial of RGX-202 to treat Duchenne muscular dystrophy (Duchenne).

RGX-202 is a one-time gene therapy that leverages the NAV AAV8 vector of REGENXBIO.

It will deliver a transgene for a new microdystrophin that comprises the functional elements of the C-Terminal domain observed in naturally seen dystrophin.

The company anticipates commencing the trial in the first half of this year with study centres planned to be launched in the US in the initial stage.

Additional trial centres will subsequently be opened in Canada and Europe.

The open-label, multicentre Phase I/II dose-escalation and dose-expansion AFFINITY DUCHENNE study will assess the safety, clinical efficacy and tolerability of a single intravenous (IV) dose of RGX-202 in Duchenne patients.

The dose-escalation phase will have six ambulatory, paediatric subjects aged four to 11 years with Duchenne enrolled in two arms to receive either 1×10¹⁴ genome copies (GC)/kg body weight and 2×10¹⁴ GC/kg body weight.

Following an independent safety data analysis for each arm, a dose-expansion phase is expected to enrol up to six additional subjects in each cohort.

RGX-202’s safety, immunogenicity analysis, pharmacodynamic and pharmacokinetic measures and strength and functional evaluations are the endpoints of the trial.

REGENXBIO chief scientific officer Olivier Danos said: “Additional therapeutic options are still needed for the treatment of Duchenne, and our trial design follows compelling evidence from preclinical studies which demonstrated that one-time treatment with RGX-202 can express meaningful levels of a novel, functional microdystrophin protein in muscle, and showed significant improvements in muscle force and function in animal models.”

Duchenne is a rare genetic disease caused by mutations in the gene responsible for producing dystrophin.

Last October, the company reported initial data from the Phase II ALTITUDE trial of RGX-314 for treating diabetic retinopathy without centre-involved diabetic macular oedema.

Cell & Gene Therapy Coverage on Clinical Trials Arena supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena